PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
(d) Exhibits
| Exhibit Number | Description |
| 1.1 | Form of Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the Securities and Exchange Commission (the “SEC”) on March28, 2018). |
| 4.1 | Form of Series A Warrant (incorporated by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the SEC on March28, 2018). |
| 4.2 | Form of Series B Warrant (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the SEC on March28, 2018). |
| 4.3 | Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.7 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the SEC on March28, 2018). |
| 99.1 | Press Release dated March29, 2018. |
Pulmatrix, Inc. ExhibitEX-99.1 2 d556634dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PULMATRIX ANNOUNCES PRICING OF $15.2 MILLION UNDERWRITTEN PUBLIC OFFERING LEXINGTON,…To view the full exhibit click here
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.